ACAD * logo

ACADIA Pharmaceuticals BMV:ACAD * Stock Report

Last Price

Mex$509.00

Market Cap

Mex$68.8b

7D

0%

1Y

60.5%

Updated

11 Oct, 2023

Data

Company Financials +

ACADIA Pharmaceuticals Inc.

BMV:ACAD * Stock Report

Market Cap: Mex$68.8b

ACAD * Stock Overview

A biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. More details

ACAD * fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 83.7% below our estimate of its fair value

Earnings are forecast to grow 61.62% per year

Earnings have grown 8.8% per year over the past 5 years

Risk Analysis

Shares are highly illiquid


My Notes

Capture your thoughts, links and company narrative

ACADIA Pharmaceuticals Inc. Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$26.1b

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$4.0b

Hualan Biological Engineering

SZSE:002007

CN¥28.9b

Yili Chuanning BiotechnologyLtd

SZSE:301301

CN¥26.9b

Price History & Performance

Summary of share price highs, lows and changes for ACADIA Pharmaceuticals
Historical stock prices
Current Share PriceUS$509.00
52 Week HighUS$509.00
52 Week LowUS$509.00
Beta0.64
1 Month Change0%
3 Month Changen/a
1 Year Change60.54%
3 Year Change-43.29%
5 Year Changen/a
Change since IPO-39.91%

Recent News & Updates

Recent updates

Shareholder Returns

ACAD *MX BiotechsMX Market
7D0%0%0%
1Y60.5%0%0%

Return vs Industry: ACAD * exceeded the MX Biotechs industry which returned -6% over the past year.

Return vs Market: ACAD * exceeded the MX Market which returned 3.7% over the past year.

Price Volatility

Is ACAD *'s price volatile compared to industry and market?
ACAD * volatility
ACAD * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: ACAD * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ACAD *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993540Steve Daviswww.acadia.com

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer’s disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.

ACADIA Pharmaceuticals Inc. Fundamentals Summary

How do ACADIA Pharmaceuticals's earnings and revenue compare to its market cap?
ACAD * fundamental statistics
Market capMex$68.75b
Earnings (TTM)-Mex$1.99b
Revenue (TTM)Mex$9.88b

7.0x

P/S Ratio

-34.6x

P/E Ratio

Is ACAD * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACAD * income statement (TTM)
RevenueUS$550.90m
Cost of RevenueUS$298.66m
Gross ProfitUS$252.24m
Other ExpensesUS$363.05m
Earnings-US$110.81m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.68
Gross Margin45.79%
Net Profit Margin-20.12%
Debt/Equity Ratio0%

How did ACAD * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/11 20:30
End of Day Share Price 2023/07/14 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ACADIA Pharmaceuticals Inc. is covered by 37 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Ishan MajumdarBaptista Research
Esther Lannie HongBerenberg